4.7 Article

ERF deletion rescues RAS deficiency in mouse embryonic stem cells

期刊

GENES & DEVELOPMENT
卷 32, 期 7-8, 页码 568-576

出版社

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gad.310086.117

关键词

2i; ERF; pluripotency; RAS; mESCs

资金

  1. La Caixa Foundation
  2. Boehringer Ingelheim Fonds
  3. Ramon y Cajal contract [RYC-2011-09242]
  4. Fundacion Botin
  5. Banco Santander through its Santander Universities Global Division
  6. Spanish Ministry of Economy and Competitiveness (European Fonds Europeen de Developpement Economique et Regional [FEDER] funds) [SAF2011-23753, SAF2014-57791-REDC]
  7. Fundacio La Marato de TV3
  8. Howard Hughes Medical Institute
  9. European Research Council [ERC617840]
  10. Spanish Ministry of Economy and Competitiveness (European FEDER funds) [SAF2013-49147-P, SAF2016-80874-P]

向作者/读者索取更多资源

MEK inhibition in combination with a glycogen synthase kinase-3 beta (GSK3 beta) inhibitor, referred as the 2i condition, favors pluripotency in embryonic stem cells (ESCs). However, the mechanisms by which the 2i condition limits ESC differentiation and whether RAS proteins are involved in this phenomenon remain poorly understood. Here we show that RAS nullyzygosity reduces the growth of mouse ESCs (mESCs) and prohibits their differentiation. Upon RAS deficiency or MEK inhibition, ERF (E twenty-six 2 [Ets2]-repressive factor), a transcriptional repressor from the ETS domain family, translocates to the nucleus, where it binds to the enhancers of pluripotency factors and key RAS targets. Remarkably, deletion of Erf rescues the proliferative defects of RAS-devoid mESCs and restores their capacity to differentiate. Furthermore, we show that Erf loss enables the development of RAS nullyzygous teratomas. In summary, this work reveals an essential role for RAS proteins in pluripotency and identifies ERF as a key mediator of the response to RAS/MEK/ERK inhibition in mESCs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Oncology

RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

Manuel Sanclemente, Patricia Nieto, Sara Garcia-Alonso, Fernando Fernandez-Garcia, Laura Esteban-Burgos, Carmen Guerra, Matthias Drosten, Eduardo Caleiras, Jorge Martinez-Torrecuadrada, David Santamaria, Monica Musteanu, Mariano Barbacid

CANCER CELL (2021)

Article Biochemistry & Molecular Biology

USP7 limits CDK1 activity throughout the cell cycle

Antonio Galarreta, Pablo Valledor, Patricia Ubieto-Capella, Vanesa Lafarga, Eduardo Zarzuela, Javier Munoz, Marcos Malumbres, Emilio Lecona, Oscar Fernandez-Capetillo

Summary: Inhibitors of USP7 lead to widespread activation of CDK1 throughout the cell cycle, causing DNA damage and toxicity to mammalian cells. Additionally, USP7 interacts with the phosphatase PP2A, facilitating its active localization in the cytoplasm, and inhibition of USP7 or PP2A results in similar changes in the phosphoproteome, including increased phosphorylation of CDK1 targets.

EMBO JOURNAL (2021)

Article Multidisciplinary Sciences

KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform

Marina Salmon, Guillem Paniagua, Carmen G. Lechuga, Fernando Fernandez-Garcia, Eduardo Zarzuela, Ruth Alvarez-Diaz, Monica Musteanu, Carmen Guerra, Eduardo Caleiras, Javier Munoz, Sagrario Ortega, Matthias Drosten, Mariano Barbacid

Summary: In mice, the KRAS locus encodes two protein isoforms, KRAS4A and KRAS4B, differing only in their C terminus via alternative splicing of distinct fourth exons. By generating a mouse strain with a terminator codon in exon 4B, researchers created a bona fide Kras4B-null allele, leading to perinatal death due to heart defects. Lack of KRAS4B expression in mice resulted in reduced proliferation of fibroblasts but could be compensated for by ectopic expression of KRAS4A.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Biochemistry & Molecular Biology

A chemical screen for modulators of mRNA translation identifies a distinct mechanism of toxicity for sphingosine kinase inhibitors

Alba Corman, Dimitris C. Kanellis, Patrycja Michalska, Maria Haggblad, Vanesa Lafarga, Jiri Bartek, Jordi Carreras-Puigvert, Oscar Fernandez-Capetillo

Summary: In this study, an image-based chemical screen was conducted to evaluate the effects of medically approved drugs and drugs under development on translation levels. The study found that certain compounds can reduce translation independently of mTOR, providing new insights for anticancer drug development.

PLOS BIOLOGY (2021)

Review Oncology

Targeting KRAS mutant lung cancer: light at the end of the tunnel

Matthias Drosten, Mariano Barbacid

Summary: This article discusses the challenges of personalized medicine in treating KRAS mutant lung adenocarcinomas and highlights the recent breakthrough in developing selective KRAS(G12C) inhibitors. The mechanisms of resistance to these inhibitors and alternative therapeutic strategies to target KRAS oncogenic signaling are also explored. The article also examines the failure of MEK and ERK inhibitors in clinical trials and the potential of targeting RAF1 as a MAPK-independent activity. These developments are likely to provide new avenues for effectively treating KRAS mutant lung adenocarcinomas.

MOLECULAR ONCOLOGY (2022)

Article Oncology

KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

Guillem Paniagua, Harrys K. C. Jacob, Oksana Brehey, Sara Garcia-Alonso, Carmen G. Lechuga, Tirso Pons, Monica Musteanu, Carmen Guerra, Matthias Drosten, Mariano Barbacid

Summary: KSR1 and KSR2 play important roles in the MAPK pathway, and overexpression of KSR1 or KSR2 can independently activate the pathway and induce cell proliferation. KSR1 requires dimerization with members of the RAF family to stimulate cell proliferation and decreases dependence on KRAS oncogenic signaling.

MOLECULAR ONCOLOGY (2022)

Editorial Material Oncology

Emerging concepts in drug discovery for cancer therapy

Matilde Murga, Oscar Fernandez-Capetillo

Summary: These are exciting times to be involved in biomedical research, especially in the field of cancer drug discovery. The transition from scientific hypothesis to testable therapy is faster than ever, aided by the emergence of new technologies. This thematic issue provides an overview of recent advances and challenges in cancer drug development, offering a broad and updated perspective for those interested in developing cancer therapies.

MOLECULAR ONCOLOGY (2022)

Review Biochemistry & Molecular Biology

Targeting the nucleolus as a therapeutic strategy in human disease

Alba Corman, Oleksandra Sirozh, Vanesa Lafarga, Oscar Fernandez-Capetillo

Summary: The nucleolus is where ribosome biogenesis takes place, which is one of the most resource-intensive processes in eukaryotic cells. It is highly responsive to growth signaling and nucleolar insults, collectively known as nucleolar stress. Nucleolar alterations are a prominent feature in various human diseases, including cancer and neurodegeneration, and are also associated with aging. There have been numerous efforts to develop compounds targeting different aspects of nucleolar activity. This article provides an overview of therapeutic opportunities and current therapies for targeting nucleoli in different pathologies.

TRENDS IN BIOCHEMICAL SCIENCES (2023)

Article Biochemistry & Molecular Biology

New regulators of the tetracycline-inducible gene expression system identified by chemical and genetic screens

Valeria Colicchia, Maria Haggblad, Oleksandra Sirozh, Bartlomiej Porebski, Mirela Balan, Xuexin Li, Louise Lidemalm, Jordi Carreras-Puigvert, Daniela Huhn, Oscar Fernandez-Capetillo

Summary: The tetR-regulated system was used to construct a human osteosarcoma cell line for inducible expression of TDP-43. Chemical screening with FDA-approved drugs identified compounds that prevented TDP-43 toxicity, but further experiments showed that these compounds inhibited doxycycline-dependent TDP-43 expression. A CRISPR/Cas9 screen revealed epigenetic regulators as potential modifiers of TDP-43 toxicity. However, G9a inhibition or TRIM28 loss also prevented doxycycline-dependent TDP-43 expression.

FEBS OPEN BIO (2022)

Editorial Material Oncology

KRAS inhibitors: going noncovalent

Matthias Drosten, Mariano Barbacid

Summary: This study identified a potent inhibitor for KRAS(G12D) and demonstrated its strong antitumor activity in preclinical models of pancreatic and colorectal cancer, especially when combined with other treatments.

MOLECULAR ONCOLOGY (2022)

Review Biochemistry & Molecular Biology

Biophysical and Computational Approaches to Study Ternary Complexes: A 'Cooperative Relationship' to Rationalize Targeted Protein Degradation

Jake A. Ward, Carles Perez-Lopez, Cristina Mayor-Ruiz

Summary: Degraders can induce the ubiquitination and degradation of disease-relevant proteins by targeting E3 ubiquitin ligases. This pharmacology offers a promising alternative to current therapeutic interventions and has the potential to broaden the range of targetable proteins. Biophysical and structural biology approaches are key in understanding degrader-induced ternary complex formation, and computational models are now being used to design new degraders. Effective crosstalk between experimental and computational strategies is crucial for advancements in the targeted protein degradation field.

CHEMBIOCHEM (2023)

Article Medicine, Research & Experimental

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Marina Salmon, Ruth Alvarez-Diaz, Coral Fustero-Torre, Oksana Brehey, Carmen G. Lechuga, Manuel Sanclemente, Fernando Fernandez-Garcia, Alejandra Lopez-Garcia, Maria Carmen Martin-Guijarro, Sandra Rodriguez-Perales, Emily Bousquet-Mur, Lucia Morales-Cacho, Francisca Mulero, Fatima Al-Shahrour, Lola Martinez, Orlando Dominguez, Eduardo Caleiras, Sagrario Ortega, Carmen Guerra, Monica Musteanu, Matthias Drosten, Mariano Barbacid

Summary: KRASG12C inhibitors have greatly improved the clinical management of KRASG12C-mutant lung adenocarcinoma patients, but resistance develops rapidly. In this study, genetically engineered mice were used to compare the efficacy and resistance between genetic ablation and pharmacological inhibition of mutant Kras. Results showed that Kras ablation effectively regressed tumors and prevented resistant cells, while treatment with sotorasib, a selective KRASG12C inhibitor, led to limited antitumor response and rapid onset of resistance. Unlike human tumors, resistance in mice was not due to mutations in RAS signaling pathways, but rather amplification of mutant Kras allele and activation of xenobiotic metabolism pathways.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Review Chemistry, Multidisciplinary

Chasing molecular glue degraders: screening approaches

Ana Domostegui, Luis Nieto-Barrado, Carles Perez-Lopez, Cristina Mayor-Ruiz

Summary: Protein-protein interactions (PPIs) are crucial for biological processes. Molecular glue degraders modulate PPIs by inducing protein proximity, thus overcoming limitations of traditional therapeutics and broadening the targetable proteome.

CHEMICAL SOCIETY REVIEWS (2022)

Review Biochemistry & Molecular Biology

Identification and selectivity profiling of small-molecule degraders via multi-omics approaches

Natalie S. Scholes, Cristina Mayor-Ruiz, Georg E. Winter

Summary: The therapeutic modality of targeted protein degradation offers a solution to the limitations of traditional pharmacology. Small-molecule degraders recruit disease-causing proteins to E3 ubiquitin ligases, leading to their ubiquitination and degradation. The integration of proteomics and functional genomics is crucial in identifying and understanding novel degraders and their mechanisms.

CELL CHEMICAL BIOLOGY (2021)

暂无数据